Pladienolide B
Modify Date: 2025-08-25 18:13:08
Pladienolide B structure
|
Common Name | Pladienolide B | ||
|---|---|---|---|---|
| CAS Number | 445493-23-2 | Molecular Weight | 536.697 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 673.8±55.0 °C at 760 mmHg | |
| Molecular Formula | C30H48O8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 209.6±25.0 °C | |
Use of Pladienolide BPladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis[1][2][3]. |
| Name | pladienolide B |
|---|---|
| Synonym | More Synonyms |
| Description | Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Pladienolide B (0.1-2 nM; 24-72 hours) inhibits human cervical carcinoma cells viability[3]. Pladienolide B (0.1-2 nM; 24-48 hours) reduces SF3b1 expression in human cervical carcinoma cells[3]. Pladienolide B induces (0.1-2 nM; 24 hours) cell cycle arrest and apoptosis[3]. Cell Viability Assay[3] Cell Line: HeLa cells Concentration: 0.1, 0.5, 1, 1.5, 2 nM Incubation Time: 24, 48, 72 hours Result: Significantly decreased cell viability, and the decrease was concentration- and time-dependent. Apoptosis Analysis[3] Cell Line: HeLa cells Concentration: 0.1, 0.5, and 2 nM Incubation Time: 24 hours Result: The apoptotic cells were highly induced at 24 hours. RT-PCR[3] Cell Line: HeLa cells Concentration: 0.1, 0.5, and 2 nM Incubation Time: 24, 48 hours Result: Induced a time- and concentration-dependent decrease in cellular SF3b1 proteins. |
| In Vivo | Pladienolide B (2.5-10 mg/kg; i.v.; daily for 5 days) has strong antitumor activities[4]. Animal Model: Female or male BALB/c nu/nu mice (7 weeks of age) (PC-3, OVCAR-3, DU-145, WiDr, and HCT-116, BSY-1 xenografts)[4] Dosage: 2.5, 5, and 10 mg/kg Administration: I.v.; daily for 5 days Result: Showed strong growth inhibitory or regressive activities against these xenografts. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 673.8±55.0 °C at 760 mmHg |
| Molecular Formula | C30H48O8 |
| Molecular Weight | 536.697 |
| Flash Point | 209.6±25.0 °C |
| Exact Mass | 536.334900 |
| LogP | 3.34 |
| Vapour Pressure | 0.0±4.7 mmHg at 25°C |
| Index of Refraction | 1.533 |
| Storage condition | -20°C |
| pladienolide B |
| Oxacyclododec-9-en-2-one, 8-(acetyloxy)-4,7-dihydroxy-12-[(1E,3E,5S)-6-[(2R,3R)-3-[(1R,2S)-2-hydroxy-1-methylbutyl]oxiranyl]-1,5-dimethyl-1,3-hexadien-1-yl]-7,11-dimethyl-, (4R,7R,8S,9E,11S,12S)- |
| (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-2-[(2E,4E,6S)-7-{(2R,3R)-3-[(2R,3S)-3-hydroxy-2-pentanyl]-2-oxiranyl}-6-methyl-2,4-heptadien-2-yl]-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl acetate |